Afleveringen
-
Welcome to another episode of Idea Collider with your host, Mike Rea.
In this engaging conversation, we delve into the world of pharmaceutical innovation and collaboration. Our guest, Dr. Nedim Pipic, a pharmaceutical expert specializing in mental and retinal health, shares his journey and passion for making a difference. Join us as we explore the unmet needs in these areas, the power of hybrid approaches and precision psychiatry, and the integration of digital therapeutics.
Discover how the industry is transforming lives through innovation while remaining patient-centric. With insights into measuring development quality, the advantages of being a private company, and the importance of collaboration, this episode will inspire you to embrace change and drive positive outcomes in the pharmaceutical landscape.
Tune in to Idea Collider today and be part of the movement toward a healthier, sustainable, and equitable future.
Chapter Summaries
[0:00:21] Introduction to today's guest, Dr. Nedim Pipic
[0:04:23] Discussion on Innovation and Growth Mindset
[0:06:44] Innovation and Patient Benefit in the Pharmaceutical Industry: A Discussion on the Importance of Return on Invention and Understanding Unmet Needs in Mental Health
[0:08:25] Innovating Mental Health: A Discussion on Precision Psychiatry and Unmet Patient Needs
[0:14:39] A Discussion on Precision Medicine and the Importance of Understanding Neurobiology in Addressing Symptoms
[0:16:39] Driving Innovation in Pharma: Importance of Early Research Collaborations and Agile Culture
[0:18:52] Discussion on Innovation and R&D in Pharmaceutical Industry
[0:20:22] Driving Innovation and Culture in a Private Pharmaceutical Company
[0:23:41] Insights on Innovation and Transformation
[0:25:46] The Importance of Seeking Inspiration Outside of the Pharma Industry: A Conversation on AI and Agile Transformation
[0:27:04] A Discussion on the Intersection of Medicine and Business in Pharmaceutical Innovation
[0:33:28] Discussion on the Future of the Pharma and Biotech Industry and the Importance of Innovation and Collaboration
[0:36:06] The Future of the Pharma Industry: Collaboration, Patient Empowerment, and Sustainability
[0:37:39] Closing Remarks
Don't forget to Like, Share, Subscribe, Rate, and Review!
Keep up with Dr. Nedim Pipic;
â LinkedIn: https://www.linkedin.com/in/nedim-pip...
â Website: http://www.boehringer-ingelheim.com
Follow Mike Rea On;
â Website: https://www.ideapharma.com/
â Twitter: https://twitter.com/ideapharma
â LinkedIn: https://www.linkedin.com/in/bigidea/
Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/
Donât forget to Subscribe, Rate, Review, Like, and Share!
To listen to more fantastic podcast episodes: https://podcast.ideapharma.com/
-
Welcome to another incredible episode of the IDEA ColliderâPharma Book Club series with your host Mike Rea. Today, Annie Duke joins us on the show to discuss her latest book, âQuit: The Power of Knowing When to Walk Away.â Annie is an Author, Professional Speaker, Decision Strategist & co-founder of The Alliance for Decision Education, a non-profit whose mission is to improve lives by empowering students through decision skills education.
In the episode, Annie Duke delves into the motivation behind her latest book, âQuit,â when quitting is a valuable option rather than sticking around, grit versus willingness to quit, and Stewartâs Butterfieldâs Quit story before founding Slack. In addition, Annie expounds on the fear of changing your mind and why most people worry about failing instead of winning.
Ultimately, she delves into the Monkey & Pedestal Model, three reasons behind building the pedestal, the kill criteria & why you should have a quitting coach!
Tune in for more!
During this episode, you will learn about;
[00:00:33] Introducing todayâs guest
[00:01:37] What motivated Annie in writing her book Quit as opposed to Thinking in Bets that lead to decision making
[00:06:40] The difference between grit & willingness to quit
[00:09:27] Why eight times more people die on the descent of Mt. Everest than climbing
[00:18:53] Muhammad Ali is the embodiment of showing how in one circumstance, Grit can be a virtue & in the other circumstance, a downfall
[00:30:20] Stewart Butterfieldâs story from one of the worldâs greatest quitter to founding Slack
[00:39:37] The fear of changing your mind & failing
[00:48:36] The monkey & pedestal model
[00:56:18] Three reasons behind building the pedestal
[01:02:38] The kill criteria & the idea of having a quitting coach
[01:10:08] Does Annie act as a quitting coach?
[01:18:51] The Reverse Sicilian concept
[01:20:17] How to connect with Annie Duke
Donât forget to Follow, Rate, Review, Like, and Share
Mentioned Books
Thinking in Bets by Annie DukeQuit: The Power of Knowing When to Walk Away by Annie DukeGrit by Angela DuckworthInto Thin Air by Jon KrakauerLetâs Connect!
Follow Alliance For Decision Education;
Website: https://alliancefordecisioneducation.org/Follow Annie Duke;
Website: https://www.annieduke.com/Twitter: https://twitter.com/AnnieDukeLinkedIn: https://www.linkedin.com/in/annie-duke/More Products
Follow Mike Rea on;
Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/To listen to more amazing podcast episodes: https://podcast.ideapharma.com/
-
Zijn er afleveringen die ontbreken?
-
Welcome to another incredible episode of the IDEA Collider series with your host Mike Rea. Today the Chief Financial Officer at Recursion, Dr. Michael Secora, joins us on the show as we discuss the industrial revolution of drug discovery. Michael is a scientist and a former equity investor.
In the episode, Michael delves into the reasons behind the incredibly fast growth at Recursion, the companyâs mission of decoding biology to radically improve lives, the relatability of data, and how Recursion builds its various data sets for drug discovery. Moreover, he expounds on how Recursion stands out against its competitors in the tech industry, the unique demographics of the Recursion team, and what differentiates Recursion from other AI discovery companies.
Tune in!
During this episode, you will learn about;
[00:23] Introducing todayâs episode
[01:29] About Michael Secora and Recursion as it is today
[04:58] Recursionâs Mission on decoding biology to improve lives radically
[08:48] Biotechnology versus BioPharma Companies
[15:00] Relatability of Data
[17:10] Recursionâs data sets & their contents
[22:13] How many terabytes of data are they in executing each experiment
[24:15] How Recursion stands out against competitors in the Tech environment
[26:23] Michaelâs approach to humility in the pharmaceutical industry
[28:28] Demographics of the Recursion team
[31:20] Recursionâs Hack Week
[34:51] The difference between AI discovery companies & Recursion
[40:11] A hint of Recursion incredible speed in delivering value proposition
[47:47] Michaelâs Book Recommendations
[50:16] How to connect with Michael & Recursion`
Donât forget to Follow, Rate, Review, Like, and Share!
Mentioned Books
Journey through Mathematics by Enrique A. GonzalezTeam of Teams by Gen. Stanley McChrystal, Tantum Collins, David Silverman & Chris FusselWhat is Life by SchrodingerLetâs Connect!
Follow Recursion on;
Website: https://www.recursion.com/LinkedIn: https://www.linkedin.com/company/recursion-pharmaceuticals/Follow Michael Secora
LinkedIn: https://www.linkedin.com/in/michael-secora-phd/
More Products
Follow Mike Rea on;
Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/
To listen to more amazing podcast episodes: https://podcast.ideapharma.com/
-
The healthcare industry is moving towards a digital revolution. With the help of digital technology, healthcare providers can now provide better and more efficient services to their patients. Digital technology has also proven to have a positive impact on patient outcomes, as well as the cost of care.
Companies such as Openwater, which focuses on creating the future of medical imaging, have been able to deliver life-saving technologies. Through the use of low-intensity ultrasound, Openwater has been able to treat diseases such as glioblastoma, depression, neurodegenerative diseases, and stroke.
In this episode, Mary Lou Jepsen, the CEO and Founder of Openwater shares how Openwater started and what it deals with. Mary Jepsen also shares how her company has transformed healthcare through digital technology. Moreover, she discusses the operating and hiring principles of the company.
Tune in for more insights!
Key Highlights
[01:44] Meet our guest; Meet our guest; Mary Lou Jepsen, and hear her backstory
[03:32] The contrast between Pharmaceutical Companies and companies such as Google & Facebook
[05:18] How we can apply physics to create interference ability and be able to see into our bodies using camera chips used in smartphones instead of using huge and expensive MRI scanners
[07:32] Why the One Laptop Per Child (OLPC) initiative didnât work
[09:35] How she co-created the worldâs first holographic video system from an idea that seemed impossible
[12:07] Physicistsâ predominant culture of looking for all the ways that they might be wrong and learning from that vs. Biologistsâ culture of looking for any proof that they are right
[17:05] Technology that uses low-intensity ultrasound on human brain organoids in glioblastoma cancer treatment which is better than chemotherapy
[18:24] How did Openwater start, and what does the company deal with?
[20:17] The use of technology to enable rapid identification of the large vessel occlusions to decrease the time to intervention in stroke victims
[26:56] Severe depression treatment using a headset capable of focusing low-frequency ultrasound on the nerve cells in the brain, which is more effective than transcranial magnetic stimulation
[31:42] The side effect of psychedelics in depression treatment
[37:00] Comparison between cost change in the consumer electronics industry and the healthcare industry
[40:21] The operating and hiring principles of the Openwater company
[49:00] How to link with Mary Lou Jepsen
Donât forget to Follow, Rate, Review, Like, and Share!
Letâs Connect!
Follow Mary Lou Jepsen on her;
Personal website:https://www.maryloujepsen.com/Company website: https://www.openwater.cc/LinkedIn: https://www.linkedin.com/in/majepsen/Twitter: https://twitter.com/mljmljmljFacebook: https://web.facebook.com/maryloujepsen?_rdc=1&_rdrMore Products
Follow Mike Rea on;
Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/To listen to more fantastic podcast episodes: https://podcast.ideapharma.com/
-
Welcome to another incredible episode of the IDEA ColliderâPharma Book Club series with your host Mike Rea. Today a competitive advantage expert, and CEO of Smart Advantage, Jaynie Smith, joins us on the show. She delves into snippets in her book, Creating Competitive Advantage, & the role of competitive advantage in increasing sales and protecting profit margins.
Moreover, she explains that itâs not about prices but your value proposition, understanding your customers' top three buying criteria, and competitive positioning. Ultimately she discusses the power of competitive advantage, implementing metrics that quantify competitive ads and focusing on the company rather than product advantage.
Tune in for more!
During this episode, you will learn about;
[00:20] Introducing todayâs episode
[01:27] About todayâs guest, âJaynie Smith.â
[05:05] The process of unpacking & looking for opportunities
[09:44] Does everyone in business understand why they are in business
[11:45] Competitive advantage is closing deals & making money in an organization
[13:43] Why companies donât spend enough time listening to their customers
[16:09] Building your value proposition
[22:28] Competitive positioning
[26:05] Do people give positioning the credit thatâs due in the business world
[30:48] Do ad agencies get competitive positioning right?
[32:20] Company versus product competitive advantage
[35:57] Why companies lose sight of things that matter most to their customers
[38:52] Persistence in communication
[40:58] How to connect with Jaynie Smith
[41:40] Book recommendations from Jaynie
Letâs Connect!
Follow Jaynie Smith on;
LinkedIn: https://www.linkedin.com/in/jayniesmith/Website: jayniesmith.comFollow Smart Advantage
Website: https://smartadvantage.com/More Products
Follow Mike Rea on;
Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharma LinkedIn: https://www.linkedin.com/in/bigidea/To listen to more amazing podcast episodes: https://podcast.ideapharma.com/
-
Welcome to another incredible episode of the IDEA ColliderâPharma Book Club series with your host Mike Rea. Today we are joined by Sherine Khalil, the Vice President and Chief Business Officer for Valor Compounding Pharmacy. She talks about sterile and non-sterile compounding as well as her transition from the nonprofit world to academic medicine.
Additionally, she delves into the major functional areas of compounding pharmacy, the reasons behind the decline in compounding pharmacy over the years, her source of ideas, and how she judges success. Moreover, Sherine expounds on the organizational structure within the pharmacy, how far she plans into the future, and her journey in business consulting.
Tune in!
During this episode, you will learn about;
[01:23] About Sherine Khalil
[05:36] Sherineâs transition from the nonprofit world to academic medicine
[11:25] Is her curiosity self-directional?
[13:55] About compounding pharmacy and its major function areas
[15:55] Reasons for the decline in compounding pharmacy over the years
[19:00] Sherineâs source of ideas. Whatâs her process of assessing development
[21:10] Organizational structure and hierarchy within the pharmacy
[22:25] How she judges success. What will work or not work
[23:54] How far Sherine plans into the future
[28:06] What her Quarter 1 & 2 goals look like for her amidst covid in 2022
[30:13] Whatâs in Sherineâs organizational structure that makes her more agile than other companies
[32:19] Sherineâs biggest idea in telehealth
[39:33] Sherineâs journey in business consultancy
[44:29] Her source of motivation
[46:36] Sherineâs book recommendations
[48:04] One thing Sherine wishes she could have been asked
[52:13] To connect with Sherine
Letâs Connect!
Follow Sherine Khalil on;
LinkedIn: https://www.linkedin.com/in/sherinekhalilEmail: [email protected]Follow Valor Compounding Pharmacy;
Website: https://valorcompounding.com/More Products
Follow Mike Rea on;
â Website: https://www.ideapharma.com/
â Twitter: https://twitter.com/ideapharma
â LinkedIn: https://www.linkedin.com/in/bigidea/
To listen to more amazing podcast episodes: https://podcast.ideapharma.com/
-
Welcome to another incredible episode of the IDEA ColliderâPharma Book Club series with your host Mike Rea. Today we are joined by Prof. Brian D Smith, a pharma innovation geek for the past 24 years. He talks about his latest book, â New Drugs, Fair Prices,â and how to manage the pharmaceutical innovation ecosystem for sustainable and affordable new medicines.
Additionally, he delves deep into discovery habitats and how every habitat contributes to the ecosystem for a sustainable and affordable supply of new medicines. Moreover, Brian expounds on an unhealthy ecosystem and three big goals to achieve in our ecosystems.
Tune in!
During this episode, you will learn about;
[00:21] Introducing the show
[01:17] About Brian Smith
[04:41] Brianâs main focus in his latest book, âNew Drugs, Fair Prices.â
[09:20] A snippet of the introduction to Brianâs new book
[14:58] Why the definition of terms was important all the way through his book
[18:36] The selection pressure in the industry
[18:57] The seven types of habitats and what they need to contribute to the ecosystem
[22:30] The innovation habitat
[25:00] Brianâs definition of an unhealthy ecosystem
[28:46] Three big goals we need to achieve through our ecosystem
[33:20] Ecosystems donât just change. How do you understand and manage them?
[42:00] Book recommendations for aspiring innovation and pharmaceutical geeks
[46:52] How to connect with Brian Smith
Letâs Connect!
Follow Brian Smith on;
Website: https://www.pragmedic.com/Youtube: https://www.youtube.com/watch?v=35HFWM6tbTcPodcast: https://podcasts.apple.com/us/podcast/darwins-medicine/id1551652841More Products
Follow Mike Rea on;
â Website: https://www.ideapharma.com/
â Twitter: https://twitter.com/ideapharma
â LinkedIn: https://www.linkedin.com/in/bigidea/
To listen to more amazing podcast episodes: https://podcast.ideapharma.com/
-
Welcome to another incredible episode of the IDEA ColliderâPharma Book Club series with your host Mike Rea. Today a tech pioneer, founder & CEO of Rapid Alpha joins us on the show as we discuss marketing intelligence & why business leaders can not ignore data quality.
Matthew talks about his career path from intellectual property to where he is now, about Rapid Alpha, what innovation management entails, and how data works and impacts company decisions. Additionally, he expounds on the right KPIs for pharmaceuticals, platforms & tools for better data organization, creating value for your company as well as the future of data.
Tune in for more!
During this episode, you will learn about;
[00:27] Introducing the episode
[00:40] Know our guest âMatthew Wahlrabâ
[04:47] His career path from intellectual property to where he is now
[12:00] How data works
[16:55] Defining innovation management
[21:16] How data impacts company decisions
[22:15] About Matthew's company Rapid Alpha & what they do
[24:48] Matthewâs special sources
[26:29] Matthewâs approach to Green flags & who should be working where
[29:49] Getting your timing right
[32:22] The right KPIs for pharmaceuticals
[37:49] Platforms & tools for better data organization
[43:04] Creating value in an enterprise
[47:52] The future of data
[51:44] Book recommendations from Matthew
[55:45] Best way to connect with Matthew Wahlrab
[56:31] One question he wishes to have been asked
Letâs Connect!
Follow Matthew Wahlrab on;
LinkedIn: https://www.linkedin.com/in/matthew-wahlrab/Follow Rapid Alpha on;
Website: https://rapidalpha.com/LinkedIn: https://www.linkedin.com/company/rapidalpha/More Products
Follow Mike Rea on;
â Website: https://www.ideapharma.com/
â Twitter: https://twitter.com/ideapharma
â LinkedIn: https://www.linkedin.com/in/bigidea/
To listen to more amazing podcast episodes:
https://podcast.ideapharma.com/
-
Welcome to another incredible episode of the IDEA ColliderâPharma Book Club series with your host Mike Rea. Today, Tim Kight, a long-life student of elite performance, coach, and Focus 3 CEO joins us on the show as we discuss developing leaders & strengthening organizational culture to achieve better results.
Tim delves into the five drivers of organizational greatness, training your team on behavioral skills, rebuilding your companyâs culture, and expanding your focus run. Additionally, he talks about replacing old habits with good ones, the twenty square ft principle, and stepping up to become an elite in your team!
Tune in for more!
During this episode, you will learn about;
[00:27] Introducing the show
[01:50] Timâs background & experience in sports & business
[05:45] Invention doesnât become innovation all by itself. What roles teams & organizations play
[07:29] 5 drivers for organizational greatness
[09:25] Talent recognition in organizations
[11:26] What to consider when hiring -Job skills vs. behavior skills.
[17:52] Leading with your heart in business
[20:43] Rethinking & rebuilding a companyâs clear, concise & compelling culture
[23:13] A quick contrast between an athletic & business team
[26:41] Planning for the future of your business. The known versus the unknown of the company's future.
[31:14] Expanding your focus run & 5 questions to ask yourself and your team
[35:50] Unlearning to relearn your skill versus replacing old habits with good ones
[38:00] Timâs twenty square ft principle
[45:37] A case study on changing culture, discipline & achieving good results
[53:00] Stepping up, confronting that default mode, and becoming elite in your team
[55:36] To connect with Tim Kight
Donât forget to Follow, Rate, Review, Like, and Share!
Letâs Connect!
Follow Tim Kight on;
â LinkedIn: https://www.linkedin.com/in/timothykight/
â Website: https://focus3.com
â Twitter: @TimothyKight
â Email: [email protected]
More Products
Follow Mike Rea on;
â Website: https://www.ideapharma.com/
â Twitter: https://twitter.com/ideapharma
â LinkedIn: https://www.linkedin.com/in/bigidea/
To listen to more amazing podcast episodes: https://podcast.ideapharma.com/
-
Welcome to another amazing episode of the IDEA ColliderâPharma Book Club series with your host Mike Rea. In todayâs episode, Mike is joined by John Waid. John is a thought leader, author, and CEO of a unique boutique global culture & leadership development firm. He talks about culture and the purpose of an organization.
Additionally, he talks about the importance of knowing your; purpose, mission, values, and principles of behavior and why most professionals who are promoted based on their skill sets fail when promoted to leadership positions. Moreover, he shares how to start building a successful workplace culture.
Tune in!
During this episode, you will learn about;
[00:22] Episode introduction
[00:36] Todayâs focus; Asymmetric learning and its impact on culture
[00:55] Know our guest; John Waid
[03:01] What is culture?
[05:41] The purpose of an organization
[10:36] Examples of companies and their values
[14:46] Why he came up with the principle of three values
[16:34] The importance of respectful spirit value
[19:19] Why you should know your; purpose, mission, values, and principles of behavior
[22:16] Why most professionals who are promoted based on their skillsets fail when promoted to leadership positions
[26:27] Chick-fil-Aâs values and culture
[32:31] Why one company outperforms the other
[37:16] Can culture be built virtually?
[40:25] How to start building a successful workplace culture
[42:53] Disruption vs Innovation
[45:09] How to connect with John Waid
Love the show? Follow, Rate, Review, Like, and Share!
Letâs Connect!
Follow John Waid on;
Website: https://www.corporatecultureconsulting.com/
LinkedIn: https://www.linkedin.com/in/johnwaid/
Facebook: https://www.facebook.com/c3culture/
More Products
Follow Mike Rea on;
Website: https://www.ideapharma.com/
Twitter: https://twitter.com/ideapharma
LinkedIn: https://www.linkedin.com/in/bigidea/
To listen to more amazing podcast episodes: https://podcast.ideapharma.com/
-
Welcome to another incredible episode of the IDEA ColliderâPharma Book Club series with your host Mike Rea. Today we are joined by a consultant, best-selling author, and one of the worldâs top experts on strategy and innovation, Rita McGrath.
In the episode, Rita talks to us about her transition from a political science career to innovation in the corporate venture, how to build an innovation program, challenges in implementation, and why you need multiple funding sources while championing an idea. Additionally, we delve into making that 10x shift in a company, discovery-driven planning, strategic inflection points & best books she would recommend.
Tune in for more innovation insights!
[02:01] About Rita McGrath
[05:10] Ritaâs books
[11:55] Tips for building an innovation program
[16:10] Why do companies have one innovation process
[18:45] Reasons companies prefer false confidence instead of the uncertain approach
[27:40] How to get an organization to make a shift to a big place
[34:11] Ritaâs thoughts on creativity
[37:25] Why you should have multiple sources of funding & approval
[37:54] Being future forward on failure & interrogating failure
[43:48] Problems related to assumptions in planning
[49:39] Discovery-driven planning
[51:01] Strategic inflection points
[55:05] Books Rita would recommend
[57:16] This or that question (Disruption or innovation)
[58:13] To connect with McGrath
Mentioned Books
Seeing Around the Corners By Rita McGrath
Market Busters By Rita McGrath
The End of Competitive Advantage By Rita McGrath
Discovery-Driven Growth By Rita McGrath
Seven Rules of Power By Jeffrey Pfeffer
Thinking Fast & Slow by Kahneman Daniel
Humor Seriously By Jennifer A Aker & Naomi Bagdonas
Letâs Connect!
To Connect With Rita McGrath;
â Website: https://www.ritamcgrath.com/
â Website: https://www.valize.com/
More Products
Follow Mike Rea on;
Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/To listen to more amazing podcast episodes: https://podcast.ideapharma.com/
-
Welcome to another incredible episode of the IDEA ColliderâPharma Book Club series with your host Mike Rea. Today we are joined by Andrew Hopkins, the Founder & CEO of Exscientia, as he talks to us about the use of AI in drug discovery.
In the episode, we delve into Andrewâs journey of developing better drug discovery methods, applying data mining in drug discovery, and the value of data integration in the pharmaceutical industry. Additionally, he expounds on what AI drugs look like and future plans for Exscientia.
Tune in!
During this episode, you will learn about;
[01:12] Introducing Andrew Hopkins & his journey to his current role
[06:27] Applying data mining approach & machine learning
[12:10] What Andrew saw that others were not seeing
[19:06] The value of data integration
[22:02] The role of asking questions & finding answers in tech or data
[26:46] How Hopkins addresses being referred to as the AI discovery group
[33:08] Active learning approaches
[39:06] What an AI drug looks like & what itâs better at
[42:17] The future of AI drugs & Exscientia future plans in establishing clinics
[46:34] What do the next couple of years look like regarding solutions Andrew wished he had 5-10 years ago?
Donât forget to Follow, Rate, Review, Like, and Share!
Mentioned Books
Ideas-A History From Fire To Freud by Peter Watson
Where Good Ideas Come From by Steven Johnson
Letâs Connect!
Follow Exscientia on;
â Website: https://www.exscientia.ai/
â LinkedIn: https://www.linkedin.com/company/ex-scientia/
More Products
Follow Mike Rea on;
Website: https://www.ideapharma.com/
Twitter: https://twitter.com/ideapharma
LinkedIn: https://www.linkedin.com/in/bigidea/
To listen to more amazing podcast episodes: https://podcast.ideapharma.com/
-
In this incredible episode, Mike Rea is joined by Dr. John L. LaMattina. John is the former Senior Vice President of Pfizer Inc and President of Pfizer Global Research & Development. Additionally, he is a senior partner at PureTech Health and an author. He talks about the misconception about Pfizerâs profiteering from the pandemic and the drug pricing in America.
John also discusses how Gileadâs Sovaldi drug for hepatitis C became overpriced in the US and the effects of insurance companies on the drug market. Moreover, he talks about the misinformation about insulin and its pricing, NIHâs role in drug discovery research, and the profitability of the pharma industry.
Tune in!
During this episode, you will learn about;
[00:22] Introduction to the show
[0:42] Know our guest; Dr. John L. LaMattina, and why he has authored his books
[04:58] Misconception about Pfizerâs profiteering from the pandemic
[08:13] Drug pricing in America
[12:35] Gileadâs Sovaldi drug for hepatitis C and how it became overpriced in the US more than in other countries
[19:57] The cost-effectiveness of PCSK9 in regulating (low-density lipoprotein) LDL cholesterol
[21:42] Effect the insurance companies have had on the drug market
[26:09] Value of the âme-tooâ drugs
[30:01] The inefficiency of the flu vaccines
[33:03] The funding for early-stage mRNA vaccines
[34:23] The input of the FDA and CDC in the manufacture of mRNA vaccines
[37:46] What is NIHâs role in drug discovery research?
[38:13] The process and cost of drug discovery; from idea to getting the drug approved
[42:39] Misinformation about insulin and its pricing
[47:21] Is the value vs. affordability of medicines a reputation challenge or a commercial challenge for the industry?
[51:31] Whatâs the profitability of the pharma industry?
[59:48] Recommended reading
[01:02:38] How to connect with us
Donât forget to Subscribe, Rate, Review, Like, and Share!
Resources Mentioned
Book; Pharma and Profits by John L. LaMattina
Book; Devalued and Distrusted by John L. LaMattina
Book; Drug Truths by John L. LaMattina
Book; The Great American Drug Deal by Peter Kolchinsky
Letâs Connect!
Website: https://www.johnlamattina.com/
Twitter: https://twitter.com/john_lamattina
LinkedIn: https://www.linkedin.com/in/john-lamattina-2985a9b/
More Products
Follow Mike Rea on;
Website: https://www.ideapharma.com/
Twitter: https://twitter.com/ideapharma
LinkedIn: https://www.linkedin.com/in/bigidea/
To listen to more fantastic podcast episodes: https://podcast.ideapharma.com/
-
Welcome to another fantastic episode of the IDEA ColliderâAsymmetric learning series with your host Mike Rea. Today we are joined by Gene Yoo, the Chief Executive Officer at Resecurity, Inc. He talks about asymmetric learning in cybersecurity & Intelligence and what gives Resecurity an edge over other competitors in the market
Moreover, he shares about the signal validation process at Resecurity, how to understand the vulnerability of your business and what you need to combat cyber threats. In addition, Gene talks about the âwhat ifâ component in their learning approach and the leadership style & culture at Resecurity.
Tune in!
During this episode, you will learn about;
[00:23] Introduction to the show
[01:23] What this series is about; Asymmetric learning
[04:41] Definition of insight in cybersecurity
[07:07] What is cyber threat intelligence about, and how should threat intelligence data be interpreted to deliver actionable insights?
[10:37] Security theater
[14:40] How Resecurity identifies a threat
[19:58] Understanding the vulnerability of your business and what you need to combat cyber threats
[22:52] Do they provide threat solutions or just threat evidence?
[24:22] The âwhat ifâ component in their learning approach
[27:36] What gives Resecurity an edge over other cybersecurity & Intelligence companies in the market?
[29:19] Signal validation process at Resecurity
[31:00] The source of their data
[34:29] Resecurity leadership style and culture
[39:40] Prototyping at Resecurity
[42:49] Does Gene prefer a disruptor or an innovator?
[44:59] Whatâs the future of Resecurity in 5 years?
(46:33] How to connect with Gene Yoo
Donât forget to Subscribe, Rate, Review, Like, and Share!
Letâs Connect!
Follow Gene Yoo on;
Website: https://resecurity.com/
LinkedIn: https://www.linkedin.com/company/resecurity/
Facebook: https://bit.ly/3vqMfzS
Twitter: https://twitter.com/RESecurity
Vimeo: https://vimeo.com/user153388997
More Products
Follow Mike Rea on;
Website: https://www.ideapharma.com/
Twitter: https://twitter.com/ideapharma
LinkedIn: https://www.linkedin.com/in/bigidea/
To listen to more amazing podcast episodes: https://podcast.ideapharma.com/
-
Welcome to another fantastic episode of the IDEA ColliderâAsymmetric learning series with your host Mike Rea. In todayâs episode, Mike interviews Steven Johnson, an author of 13 books, a TV host, and a podcaster. He talks about Innovation vs. Invention and explains where good ideas come from.
Additionally, Steven talks about the Individual and organizational hunch collection tools and shares how organizational culture impacts innovation. Moreover, he talks about his books The Ghost Map and Farsighted.
Tune in!
During this episode, you will learn about;
[01:05] Meet Steven Johnson and hear his backstory
[03:03] Innovation vs. Invention
[05:26] Where do good ideas âsoul hunchesâ come from?
[09:32] Reason why play and delight are linked to profound innovation
[12:52] Organizational culture and innovation
[17:12] How the daily schedule for his writing work looks like
[10:1414] Stevenâs discovery process
[26:59] How Steven uses Twitter as a source of scientific discovery
[30:58] Individual and organizational hunch collection tools
[39:10] The Ghost Map and how it evolved from the format to a published book
[46:34] Farsighted: How We Make the Decisions That Matter the Most
[55:11] How to connect with Steven Johnson
Remember to Follow, Rate, Review, Like, and Share!
Resources Mentioned
Book; The Ghost Map by Steven Johnson
Book; Farsighted by Steven Johnson
Book; How We Got to Now by Steven Johnson
Book: Wonderland by Steven Johnson
Letâs Connect!
Follow Steven Johnson on;
Website: https://stevenberlinjohnson.com/
Twitter: https://twitter.com/stevenbjohnson
Subscribe to his Newsletter at: https://adjacentpossible.substack.com/about
To grab a copy of any of Stevenâs Books: https://amzn.to/3L3zUrV
More Products
Follow Mike Rea on;
Website: https://www.ideapharma.com/
Twitter: https://twitter.com/ideapharma
LinkedIn: https://www.linkedin.com/in/bigidea/
To listen to more fantastic podcast episodes: https://podcast.ideapharma.com/
-
Welcome to another fantastic episode of the IDEA ColliderâPharma Book Club series with your host Mike Rea. Today we are joined by Billy Kenber, an investigative journalist at âThe Times.â He talks about his journey to writing his book âSick Moneyâ and the content in the book.
Additionally, he talks about the pharmaceutical industryâs social contract with patients and how its distortion has led to pharmaceutical greed. Moreover, he shares how the culture within the pharmaceutical industry has changed, why drug companies overprice the drugs, and what can be done to regulate drug pricing.
Tune in!
During this episode, you will learn about;
[00:22] Episode introduction
[01:08] Meet our guest; Billy Kenber
[01:22] His journey to writing his book âSick Moneyâ
[03:28] What the book is about
[06:11] How Concordia Pharmaceuticals & Valeant Pharmaceuticals companies
grew quickly and gained a short-term monopoly, thus hiking the drug prices
[10:40] Whatâs the geographical scope of the pharmaceutical fraud
[12:47] Pharmaceutical industryâs social contract with patients and how its distortion has led to pharmaceutical greed
[15:20] The first AIDS drug; AZT
[18:30] A background of AZT drug high pricing and how it led to other
pharmaceutical companies raising their prices
[22:47] How Pharmacy Benefit Managers (PBMs) raise drug prices for patients
[25:39] The âDirty Pharmaâ chapter in his book
[28:45] Why drug companies overprice the drugs
[29:17] How the culture within the pharmaceutical industry has changed
[30:52] Pharmaceutical innovation after World War II; Antibiotics
[35:29] mRNA vaccines in the COVID-19 pandemic
[37:28] Effect of cultural changes in the pharmaceutical industry on the drugs we
get and how Research and Development (R&D) is done
[40:30] How cultural changes have affected orphan drugs and cancer drugs
[46:30] What can be done to regulate drug pricing?
[53:50] Recommended reading
[56:00] How to connect with Billy
Love the show? Follow, Rate, Review, Like, and Share!
Letâs Connect!
Follow Billy Kenber on his;
Website: https://www.billykenber.com/
Twitter: https://twitter.com/billykenber
Linkt.ree: https://linktr.ee/billykenber
To grab a copy of the âSick Moneyâ book: https://amzn.to/3N4XJPD
More Products
Follow Mike Rea on;
Website: https://www.ideapharma.com/
Twitter: https://twitter.com/ideapharma
LinkedIn: https://www.linkedin.com/in/bigidea/
To listen to more amazing podcast episodes: https://podcast.ideapharma.com/
-
Kabir Nath is President & CEO, Otsuka North America Pharmaceutical Business Throughout his career, Kabir has built bridges between cultures. His work has taken him across the globe, spanning 3 continents and multiple countries. Kabir has lived and worked in the United Kingdom, France, Spain, India, Singapore, China, and the United States. He has consistently inspired those around him to go beyond cultural and linguistic differences to bring new concepts and ideas to life, forging stronger partnerships rooted in diverse experiences.
For Kabir, leadership is not about having all the answers, rather, it is about creating an environment where Otsuka-people are deeply connected to their purpose, and the patients and families they serve. In his nearly 30 years of broad international biopharmaceutical and medical-device experience, Kabir has shaped strategy to deliver results in complex, challenging business environments at the country, regional, and global level. Otsuka, with its unique blend of Japanese and American cultures, is the place where Kabir puts his purpose into practice daily. Kabir joined Otsuka in March 2016 to head all commercial operations within the North American pharmaceutical businesses. Most recently, Kabir was appointed Senior Managing Director, Global Pharmaceutical Business at Otsuka, with overall operational leadership for the global pharmaceutical business, overseeing North America, Europe, Japan, and the rest of Asia, while continuing to have direct responsibility for the US business.
Before joining Otsuka, Kabir held strategic and senior operational roles across several continents at Bristol-Myers Squibb (BMS). He began his career in strategy consulting at Booz Allen & Hamilton before holding a wide range of operational and strategic roles at the medical technology company Smith + Nephew. Kabir holds an MA from Kingâs College, University of Cambridge, and an MBA with Distinction from INSEAD.
-
(Now also released in paperback: https://amzn.to/3lWjo2B)
Kat can be found at First Create The Media: and on Twitter: @Kat_Arney
Find out more about Rebel Cell here: https://www.rebelcellbook.com/about-rebel-cell-cancer-book
Many of us think of cancer as a contemporary killer, a disease of our own making caused by our modern lifestyles. But, as Kat Arney explains in her new book REBEL CELL: Cancer Evolution and the Science of Life, that perception just isnât true. Although it might be rare in many species, cancer is the enemy lurking within almost every living creature. Why? Because cancer is a bug in the system of life. We get cancer because we can't not get it.
Cancer has always been with us. It killed our hominid ancestors, the mammals they evolved from and the dinosaurs that trampled the ground before that. Tumours grow in pets, livestock and wild animals. Even tiny jelly-like Hydra - creatures that are little more than a tube full of water - can get cancer.
Cancer starts when cells rebel against the social norms of the body, throwing off their molecular shackles and growing out of control in a shambolic mockery of normal life. This is why we can't avoid cancer: because the very genes that drive it are essential for life itself.
The revolution has raged, on and off, for millions of years. But it was only in the twentieth century that doctors and scientists made any significant progress in understanding and treating cancer, and it is only in the past few decades that weâve finally begun to kick the mobâs malignant arse.Now the game is changing. Scientists have infiltrated cancer's cellular rebellion and are finally learning its secrets. Seeing cancer in a new way â as rebel cells adapting and evolving within the landscape of the body â is pointing towards new ways of preventing and controlling cancer in the long term or even driving it to extinction altogether.
In REBEL CELL, geneticist and science writer Kat Arney reveals that:
Modern lifestyles canât take all the blame â Cancer has been around for millions of years and affects almost all multicellular organisms, with some notable exceptions. Sponges and comb jellies are remarkably cancer-resistant, for example, although the reason why is still a mystery.
Cancer cells are cheats that break the rules â From cells all the way up to human cities, societies function best when everyone obeys the rules. Cancer cells are cheats in the system, bending or completely breaking the rules to their advantage.
Cancer is an inevitable part of life â Genetic alterations (mutations) are the fuel for evolution â the force that shaped all life on earth. But this same force is at work within cancer, enabling them to adapt and evolve resistance to treatment.
Mutations are much more common than we thought â As we age, our bodies become a patchwork of mutated cells, yet most of these donât become cancerous. The big question is why?
The quest for a cure has derailed our thinking â Focusing on âmagic bulletsâ and pricey wonder drugs has led us away from potentially transformative approaches to preventing and treating cancer based on evolutionary ideas.
REBEL CELL: Cancer Evolution and the Science of Life takes the reader back to the dawn of life on planet earth right up to the present day to get to the heart of what cancer really is and how by better understanding it we might one day overcome it.
-
As President of Novartis Oncology, Susanne Schaffert is pursuing a bold strategy to reimagine the research, development and commercialization of innovative treatments that will help improve and extend the lives of people with cancer and related blood disorders.
Susanne has held positions of increasing seniority across a range of business areas during her career at Novartis, having first joined the company as a sales representative in Germany in 1995. The majority of her roles have been in oncology, where she has a passion for making a difference in the lives of patients.
Prior to her current position, she served as President of Advanced Accelerator Applications, a Novartis company focused on the development of products for targeted radioligand therapy and precision imaging. Today, she leads more than 10 000 employees in 85 countries working to transform cancer care across four distinct therapeutic platforms.
Susanne is a respected business leader and scientist who was featured in Fortuneâs âMost Powerful Women Internationalâ list in both 2019 and 2020. She actively mentors women at Novartis and encourages them to seek leadership roles. Susanne has a background in science and holds a doctorate in organic chemistry from the University of Erlangen in Germany, but as a former ballet dancer, she is also passionate about the arts. This dual interest informs her leadership philosophy, which celebrates diversity of thought and ideas as one of the keys to bold innovation.
Susanne also holds leadership positions in the broader pharmaceutical industry. She serves on the board and executive committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA), and is vice chair of EFPIAâs Patient Access Committee.
Susanne on LinkedIn: https://www.linkedin.com/in/susanne-schaffert-830b7053
- Laat meer zien
